Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host In...

Full "IntellAsia: Resources" article